|
JP2020201232A
|
|
Allergy antigen and epitope thereof
|
|
JP2019182845A
|
|
Kynurenine aminotransferase 2 (kat2) inhibitor
|
|
JP2020158438A
|
|
Cancer metastasis inhibitor
|
|
JP2019151621A
|
|
Composition for cancer therapy containing compound having kat inhibitory activity
|
|
JP2020132575A
|
|
Angiogenesis inducing agent
|
|
JP2020115841A
|
|
Method for creating experimental animal model with lymphocytic infundibuloneurohypophysitis
|
|
JP2020030120A
|
|
Evaluation method of disease onset possibility
|
|
JP2019010093A
|
|
Samples for cervical cancer examination
|
|
JP2019193709A
|
|
Amyloid-β removal system
|
|
JP2019187919A
|
|
Movement support device
|
|
JP2019050796A
|
|
Highly efficient method for artificially synthesizing rotavirus
|
|
JP2018203709A
|
|
Aβ REMOVAL SYSTEM
|
|
JP2018139580A
|
|
iPS CELL GROUP HAVING DIFFERENT MITOCHONDRIAL DISEASE INDUCED VARIANT mtDNA RATIO
|
|
JP2019038772A
|
|
Cytocidal agents
|
|
JP2019000017A
|
|
Method for identifying individuals with sensitivity or resistance to deamidated wheat protein allergy
|
|
JP2017192383A
|
|
Methods for detecting fetal components
|
|
JP2018011527A
|
|
Method of purifying hypothalamic precursor cell and use thereof
|
|
JP2017044584A
|
|
Swine edema disease diagnosis
|
|
JP2016056165A
|
|
ANTIBODY FORMULATIONS AND ANTIBODY KITS FOR DIAGNOSIS OR TREATMENT OF CANCER OR TUMOR UTILIZING ANTI-α6β4-INTEGRIN ANTIBODIES
|
|
JP2016131541A
|
|
Transgenic non-human mammal and its application
|
